MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)

• Status: Terminated
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and tolerability of MK6186 and the change from baseline in plasma HIV-1 RNA after seven consecutive days of dosing.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Other than HIV infection, patient's baseline health is judged to be stable

• Patient is documented HIV-1 positive

• Patient has not received an investigational agent or licensed ART with in the past 30 days

Exclusion Criteria:

• Patient has a history of stroke, chronic seizures, or major neurological disease

• Patient has a history of cancer

• Patient has used any immune therapy agents or immunosuppressive therapy within the past month

• Patient requires or anticipates the use of any prescription or non-prescription drugs during the study

• Patient has a current diagnosis of acute hepatitis, has a history of Hepatitis C or has positive Hepatitis B surface antigen

• Patient consumes excessive amounts of alcohol (greater than 3 servings per day) or caffeine (greater than 6 servings per day)

• Patient is an excessive smoker (more than 10 cigarettes per day)

• Patient has had major surgery, donated blood or participated in another investigational study within the past 4 weeks